Articles from MindMaze Therapeutics

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as Chief Executive Officer. Mr. Henderson joins at a pivotal inflection point as the Company invests in scaling its existing commercial presence, focused on accelerating adoption of its FDA-cleared platform in the United States to address the widening supply-demand gap in neurological care.

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today provided a post-listing corporate update and published its March 2026 investor presentation.